Search
Search Results
-
Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy
High platelet reactivity (HPR) on clopidogrel is an established thrombotic risk factor after percutaneous coronary intervention (PCI). The...
-
Gefapixant, a Novel P2X3 Antagonist, Protects against Post Myocardial Infarction Cardiac Dysfunction and Remodeling Via Suppressing NLRP3 Inflammasome
ObjectiveThe ATP responsive P2 purinergic receptors can be subdivided into metabotropic P2X family and ionotropic P2Y family. Among these, P2X3 is a...
-
The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
PurposeOutcomes from randomized controlled trials (RCTs) inform the latest recommendations on percutaneous coronary intervention (PCI) management of...
-
Complementary Pharmacotherapy for STEMI Undergoing Primary PCI: An Evidence-Based Clinical Approach
Antithrombotic therapy is the cornerstone of pharmacological treatment in patients undergoing primary percutaneous coronary intervention (PCI)....
-
Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment
Purpose of ReviewPolyvascular disease has a significant global burden and is associated with increased risk of major adverse cardiac events with each...
-
Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT)
Chronic kidney disease (CKD) increases the risk of adverse outcomes in acute coronary syndrome (ACS). The optimal regimen of dual antiplatelet...
-
Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial
BackgroundDual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 inhibitor is recommended for patients with coronary heart disease (CHD)...
-
Real-world evidence of switching P2Y12 receptor–inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry
BackgroundPotent P2Y 12 inhibitors are recommended for up to 12 months after percutaneous coronary intervention (PCI) in patients diagnosed with...
-
Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany
PurposeThe WHO 2016 re-classification of myeloproliferative neoplasms resulted in a separation of essential thrombocythemia (ET) from the...
-
Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial
BackgroundHigh on-treatment platelet reactivity (HTPR) remains a major problem in the acute management of ST-elevation myocardial infarction (STEMI),...
-
Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective
ObjectivesThe objective of this study was to evaluate a US hospital’s cost implications and outcomes of cangrelor use in percutaneous coronary...
-
Abbreviated Dual Antiplatelet Therapy Followed by P2Y12 Inhibitor Monotherapy versus 12 Months’ Dual Antiplatelet Therapy Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis of Randomized Controlled Trials
IntroductionAn increased incidence of stent thrombosis after implantation of first-generation drug-eluting stents led to a recommendation of dual...
-
Role of ATP in migraine mechanisms: focus on P2X3 receptors
Migraine is a major health burden worldwide with complex pathophysiology and multifarious underlying mechanisms. One poorly understood issue concerns...
-
Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial
IntroductionThe POPular Genetics trial demonstrated that a CYP2C19 genotype-guided P2Y 12 inhibitor strategy reduced bleeding rates compared with...
-
-
Microglia Modulate Cortical Spreading Depolarizations After Ischemic Stroke: A Narrative Review
Cortical spreading depolarizations (CSDs) are characterized by waves of diminished electroencephalography activity that propagate across the cortex...
-
Endothelial biomarkers and platelet reactivity on ticagrelor versus clopidogrel in patients after acute coronary syndrome with and without concomitant type 2 diabetes: a preliminary observational study
BackgroundPleiotropic effects have been implicated in clinical benefits of ticagrelor compared to thienopyridine P2Y 12 antagonists. There are...
-
Perioperative Guidelines on Antiplatelet and Anticoagulant Agents: 2022 Update
Purpose of ReviewMultiple guidelines and recommendations have been written to address the perioperative management of antiplatelet and anticoagulant...
-
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease
Switching P2Y 12 inhibitors is common in clinical practice. However, data on the pharmacodynamic (PD) effects of switching in clinical settings...
-
Assessment of redundant randomized clinical trials among patients with ST segment elevation myocardial infarction
BackgroundRedundant clinical trials waste resources and unnecessarily put patients at risk for harm. The objectives of the study were to assess...
